Investing.com - Financial Markets Worldwide

Collegium pharmaceutical CFO sells shares worth $313,412

Published 13/03/2025, 21:52
Collegium pharmaceutical CFO sells shares worth $313,412
COLL
-0.03%

Colleen Tupper, the Executive Vice President and Chief Financial Officer of Collegium Pharmaceutical , Inc. (NASDAQ:COLL), recently sold 10,445 shares of the company’s common stock. The company, currently valued at $919 million, has maintained impressive gross profit margins of 87% and trades at a P/E ratio of 13.7. The transaction, which took place on March 11, 2025, was executed under a Rule 10b5-1 trading plan established by Tupper on August 14, 2024. The shares were sold at a weighted average price of $30.006 per share, with the total sale amounting to approximately $313,412. Following this transaction, Tupper retains ownership of 165,246 shares in the company. According to InvestingPro analysis, analysts maintain a positive outlook with price targets ranging from $36 to $50, suggesting potential upside. InvestingPro subscribers can access 8 additional key insights about COLL’s valuation and growth prospects.

In other recent news, Collegium Pharmaceuticals reported its fourth-quarter 2024 earnings, exceeding analyst expectations with an earnings per share (EPS) of $1.75, compared to the anticipated $1.66. The company also surpassed revenue forecasts, posting $181.9 million against the projected $179.48 million. This marks a significant 22% year-over-year increase in quarterly revenue, driven by strong demand for its ADHD medication, Jornay, and pain management products, BELBUCA and Xtampza ER. Collegium’s annual revenue for 2024 reached $631.4 million, an 11% rise from the previous year. The company projects net product revenue between $735 million and $750 million for 2025, with expected growth in adjusted EBITDA by over 10%. Analyst firms have noted the company’s strong operational execution and successful product strategies. Additionally, Collegium has announced plans to expand its sales force and invest in digital marketing to support further growth.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.